- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.04. | After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe | ||
| 03.04. | Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors | ||
| 03.04. | Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief | ||
| 03.04. | FDA inspection operations face risk of further disruption amid mass HHS layoffs: report | ||
| 03.04. | Havas Health adds execs at nascent New York agency as Real Chemistry strengthens in Europe | ||
| 02.04. | With biosimilar competition looming, Roche takes a hit with failure of high-dose Ocrevus | ||
| 02.04. | For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty | ||
| 02.04. | Japan's Marubeni takes on Sumitomo's Asia pharma business to make new company in deal worth up to $480M | ||
| 02.04. | Amid uncertainty in the US, Boehringer Ingelheim projects 'slight' revenue increase for '25 | ||
| 02.04. | FDA taps insider Scott Steele to lead CBER on acting basis after Peter Marks departure | ||
| 02.04. | Gene therapy CDMO Artis BioSolutions launches with acquisition of Landmark Bio | ||
| 02.04. | Cellares' cell therapy factory-in-a-box scores coveted advanced manufacturing technology tag from FDA | ||
| 01.04. | Axsome's Sunosi comes up short in trial but shows promise in treating MDD with daytime sleepiness | ||
| 01.04. | Lilly continues full-court press against breast cancer with women's March Madness event sponsorships | ||
| 01.04. | DC court backs HHS in rejecting Vertex's proposed fertility support program for Casgevy patients | ||
| 01.04. | After dismissal of 3rd bankruptcy settlement, Johnson & Johnson says it will take on talc cases in court | ||
| 01.04. | Pharma majors put lobbyists to work to stagger tariff rollout: Reuters | ||
| 01.04. | Switzerland's SHL Medical debuts $220M autoinjector plant in South Carolina | ||
| 01.04. | FDA's new commissioner Marty Makary signed off on Peter Marks ouster: Politico | ||
| 31.03. | AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery | ||
| 31.03. | FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks | ||
| 31.03. | Judge levies $1.64B penalty on Johnson & Johnson in HIV drug marketing case | ||
| 31.03. | As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits | ||
| 31.03. | Merck's Winrevair slashes mortality-morbidity risk by 76% | ||
| 28.03. | Pharma Marketing in 2025: A Conversation with Fierce Pharma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
